PT Kalbe Farma Tbk.
PTKFF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.18 | -0.90 | 0.51 | 0.41 |
| FCF Yield | 1.43% | 1.44% | 0.35% | 1.45% |
| EV / EBITDA | 40.33 | 40.93 | 35.00 | 54.28 |
| Quality | ||||
| ROIC | 2.42% | 3.20% | 4.06% | 3.19% |
| Gross Margin | 38.10% | 40.68% | 41.56% | 41.01% |
| Cash Conversion Ratio | 1.37 | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -5.64% | 3.35% | 3.59% | 4.09% |
| Free Cash Flow Growth | -99.99% | 300.99% | -80.31% | 14.66% |
| Safety | ||||
| Net Debt / EBITDA | -3.25 | -2.33 | -2.63 | -3.40 |
| Interest Coverage | 60.08 | 101.20 | 146.32 | 70.39 |
| Efficiency | ||||
| Inventory Turnover | 0.77 | 0.71 | 0.79 | 0.76 |
| Cash Conversion Cycle | 139.36 | 151.60 | 139.71 | 137.61 |